Pharmaceutical giant Eli Lilly has unveiled plans to invest an additional $4.5 billion into its Lebanon campus in Indiana. This commitment brings the company’s total investment in its home state to $21 billion since 2020, underscoring its commitment to onshoring the pharmaceutical supply chain.
Focus: Next-gen obesity drugs and record-breaking API facility The new funding will expand operations across two key sites within the Lebanon campus:
-
Active Pharmaceutical Ingredient (API) Facility: This site will be tailored to manufacture ingredients for Foundayo (orforglipron), the recently approved oral weight loss drug currently launching in the US. It will also produce the active ingredient for retatrutide (a “triple-G” agonist), currently in late-stage trials for obesity and type 2 diabetes.
-
Record Scale: Set to open in 2027, Lilly claims this will be the largest API production site in United States history once operational.
Breakthrough in Genetic Medicines On May 6, 2026, Lilly officially opened the Lebanon Advanced Therapies site, its first production center dedicated to genetic medicines:
-
Full Spectrum Operations: The center will handle everything from research-stage development to both clinical and commercial-scale manufacturing.
-
Tech Integration: Lilly intends to implement new process designs and technologies, potentially leveraging Artificial Intelligence (AI) following its significant recent investments in the field.
-
Potential Pipeline: The site is expected to produce gene therapies such as ixoberogene soroparvovec (for wet AMD), an asset acquired through the buyout of Adverum in late 2025.
Strategic Context Lilly’s rapid expansion comes as the Trump administration looks to onshore drug manufacturing to the US to bolster the national supply chain. Alongside physical expansion, Lilly continues its aggressive dealmaking streak, having signed six M&A deals in 2026 alone, including the $2.3 billion acquisition of blood cancer specialist Ajax Therapeutics.